Global private equity and venture capital news and research

Posts Tagged ‘SV Life Sciences’

27 May 2016

SV Life Sciences raises $273.5m for Fund VI

dollar-bill-1088855_1920 Specialist venture capital firm SV Life Sciences has moved past the halfway mark for its $400m-targeting sixth fund, AltAssets can reveal.

3 December 2015

SV Life Sciences among consortium backing £19m Kesios Therapeutics Series A

microscope-275984_1920 SV Life Sciences and Imperial Innovations were among a syndicate of investors in a £19m Series A financing round for cancer treatment business Kesios Therapeutics.

22 October 2015

SV Life Sciences picked to manage $100m dementia treatment fund

dependent-100345_640 Specialist venture capital firm SV Life Sciences has been hired to manage a new $100m investment fund aimed at supporting and developing novel treatments for dementia.

9 December 2014

VC-backed CardioKinetix lands $50m in new round

heart-shape-1442152-m US medical device firm CardioKinetix has closed a $50m financing round which include backing from several venture capital firms.

14 October 2014

Bicycle Therapeutics VC backers return for £20m financing round

Bicycle Therapeutics A string of venture capital firms have renewed their commitment to UK-based biotech business Bicycle Therapeutics through a £20m financing round.

8 July 2014

SV Life Sciences hires ex-Edison Ventures general partner Balmuth

balmuth SV Life Sciences has hired experienced venture capital investor Michael Balmuth as a partner in its healthcare services team not long after adding three new venture partners to its biotechnology investment division.

3 June 2014

SV Life Sciences brings in trio of venture partners for biotech investment team

microscope7_sq Specialist venture capital firm SV Life Sciences has hired a trio of new venture partners for its biotechnology investment team.

16 April 2014

Biopharma developer PanOptica scores $45m Series B investment

Biopharmaceutical company PanOptica has raised up to $45m in a Series B financing, co-led by new participant Novo Ventures and existing investor Third Rock Ventures, alongside founding investor SV Life Sciences.

1 April 2014

Investors exit biopharma services company Aptiv in $144m sale

Investors including the Halifax Group, SV Life Sciences and Comvest Partners have exited their stake in biopharmaceutical and medical device development services company Aptiv Solutions to ICON for $143.5m.

25 February 2014

Novo Ventures leads $49m Series B for anti-acne business Thesan Pharmaceuticals

skin5_lrg Biotechnology business Thesan Pharmaceuticals, which aims to treat skin disorders including acne and dermatitis, has picked up $49m of Series B financing led by existing backer Novo Ventures.

Page 1 of 212

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016